ASCO 2026: CEACAM5-Targeted CAR-T Therapy Achieves 57.1% Objective Response Rate Using One-Tenth of Conventional CAR-T Cell Doses
On June 2, 2026, Chongqing Precision Biotech presented Phase I clinical data at the American Society of Clinical Oncology (ASCO) Annual Meeting for its proprietary rapid-manufactured, IL-9–secreting CEACAM5-targeted CAR-T cell therapy administered via intraperitoneal infusion in patients with advanced colorectal cancer with peritoneal metastases (CRPM).
Learn More +